Cynthia Robinson

MedicineSocial SciencesHealth Professions

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial”.

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

The Lancet Infectious Diseases(2021)10.1016/s1473-3099(21)00125-0

N/A

1.7DataRank · unranked

95 citations

Daniela Manno, Muhammed O. Afolabi, Babajide Keshinro, Viki Bockstal, Baimba Rogers +87 more

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study

PLoS ONE(2022)10.1371/journal.pone.0274906

N/A

1.3DataRank · unranked

32 citations

Georgi Shukarev, Chelsea McLean, Neil Goldstein, Stephan Bart, Auguste Gaddah +13 more

Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study

Vaccines(2024)10.3390/vaccines12020210

N/A

0.348DataRank · unranked

7 citations

Andrew J. Pollard, Catherine Schmidt‐Mutter, Fabrice Lainé, George PrayGod, Hannah Kibuuka +13 more

Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study

The Journal of Infectious Diseases(2020)10.1093/infdis/jiaa586

N/A

0DataRank · unranked

40 citations

Viki Bockstal, Stephan Bart, Kerstin Lühn, Cynthia Robinson, Auguste Gaddah +3 more

Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate

npj Vaccines(2020)10.1038/s41541-020-00261-9

N/A

0DataRank · unranked

75 citations

Jenny Hendriks, Thierry Van Effelterre, Bart Spiessens, Liesbeth Dekking, Laura Solforosi +24 more

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

npj Vaccines(2022)10.1038/s41541-022-00564-z

N/A

0DataRank · unranked

21 citations

Maarten Leyssen, Dirk Heerwegh, Bart Spiessens, Cynthia Robinson, Jeroen N. Stoop +13 more

Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory

EBioMedicine(2023)10.1016/j.ebiom.2023.104562

N/A

0DataRank · unranked

10 citations

Houreratou Barry, Mark Kieh, Zacchaeus Anywaine, Baimba Rogers, Seydou Doumbia +22 more